Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Nicotimide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or MPT or EC 2.4.2.12) - Overview
Nicotimide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or MPT or EC 2.4.2.12) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Nicotimide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or MPT or EC 2.4.2.12) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nicotimide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or MPT or EC 2.4.2.12) - Companies Involved in Therapeutics Development
AbbVie Inc
Angelini Group
Aqualung Therapeutics Corp
Aurigene Discovery Technologies Ltd
Calico LLC
Eli Lilly and Co
Genentech Inc
Karyopharm Therapeutics Inc
OncoTartis Inc
Tianjin Hemay Pharmaceutical Co Ltd
Nicotimide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or MPT or EC 2.4.2.12) - Drug Profiles
AU-4869 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit MPT for Inflammation and Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emptcumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GNE-617 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hemay-088 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KPT-9274 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LSN-3154567 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OT-82 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P7-C3A20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate MPT for Neurological Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MPT for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STF-118804 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nicotimide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or MPT or EC 2.4.2.12) - Dormant Products
Nicotimide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or MPT or EC 2.4.2.12) - Discontinued Products
Nicotimide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or MPT or EC 2.4.2.12) - Product Development Milestones
Featured News & Press Releases
Dec 05, 2019: Aqualung Therapeutics to present new data at Biotech Showcase Investor Conference
Aug 20, 2019: Aqualung Therapeutics receives $225 thousand dollar tiol Institute of Health (NIH) grant to establish biomarker panel for patients with acute respiratory distress syndrome
Jun 05, 2019: Aqualung Therapeutics receives a $1.7 Million tiol Institute Of Health (NIH) Fastrack Award To develop an novel immune-based therapeutic antibody for critically ill patients with acute lung injury
Mar 19, 2018: Karyopharm to Present Preclinical Data on KPT-9274 at the American Association for Cancer Research 2018 Annual Meeting
Sep 08, 2017: Karyopharm Announces Presentation of KPT-9274 Clinical Data at European Society of Medical Oncology 2017 Annual Meeting
Aug 30, 2017: Karyopharm Announces the Presentation of KPT-9274 Clinical Data at the European Society of Medical Oncology 2017 Annual Meeting
Aug 01, 2016: Pharmatek, a San Diego based contract development & manufacturing company, started the development of OT-82 dosage form for human clinical studies
Jun 27, 2016: OncoTartis: Initiated OT-82 GLP Toxicology and Safety Pharmacology studies
Jun 22, 2016: Karyopharm Initiates Phase 1 Clinical Trial with KPT-9274
Mar 16, 2016: Karyopharm to Present Data on Oncology drug KPT-9274 at the 2016 American Association for Cancer Research Annual Meeting
Mar 15, 2016: OncoTartis Provides Update on OT-82
Apr 18, 2015: Aurigene to Present its MPT Inhibitors Programs at AACR 2015
Mar 30, 2015: Oncotartis in collaboration with scientists from the Children’s Cancer Institute of Australia for Medical Research initiated testing of OT-82
Oct 30, 2014: OncoTartis Provides Update on Toxicology study of OT-82
May 16, 2014: nosyn, a Santa Clara, CA based chemistry CRO, completed process development for scaling up and manufacturing OT-82 drug candidate on a kilo scale
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AbbVie Inc, H2 2019
Pipeline by Angelini Group, H2 2019
Pipeline by Aqualung Therapeutics Corp, H2 2019
Pipeline by Aurigene Discovery Technologies Ltd, H2 2019
Pipeline by Calico LLC, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by Genentech Inc, H2 2019
Pipeline by Karyopharm Therapeutics Inc, H2 2019
Pipeline by OncoTartis Inc, H2 2019
Pipeline by Tianjin Hemay Pharmaceutical Co Ltd, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019